Innate Pharma (IPHYF) Short Interest Ratio & Short Volume $2.90 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Short Interest Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Innate Pharma Short Interest DataInnate Pharma (IPHYF) has a short interest of 500 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 0 shares to cover all short positions.Current Short Interest500 sharesPrevious Short Interest500 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$1,450.00Short Interest Ratio0.0 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares83,830,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume0 sharesAverage Trading Volume0 sharesToday's Volume Vs. AverageNaN Short Selling Innate Pharma? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHYF Short Interest Over TimeIPHYF Days to Cover Over TimeIPHYF Percentage of Float Shorted Over Time Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2025500 shares $1,450.00 No ChangeN/A0 $2.90 1/15/2025500 shares $1,450.00 No ChangeN/A0 $2.90 12/31/2024500 shares $1,450.00 -94.1%N/A5 $2.90 12/15/20248,400 shares $24,360.00 +425.0%N/A21 $2.90 11/30/20241,600 shares $2,048.00 -61.9%N/A0 $1.28 11/15/20244,200 shares $5,376.00 -14.3%N/A42 $1.28 10/31/20244,900 shares $11,000.50 -17.0%N/A0 $2.25 10/15/20245,900 shares $13,245.50 -1.7%N/A0 $2.25 9/30/20246,000 shares $13,470.00 +22.5%N/A10 $2.25 9/15/20244,900 shares $11,270.00 No ChangeN/A0 $2.30 Get the Latest News and Ratings for IPHYF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 8/31/20244,900 shares $11,270.00 -21.0%N/A24.5 $2.30 8/15/20246,200 shares $13,020.00 -8.8%N/A12.4 $2.10 7/31/20246,800 shares $13,124.68 +23.6%N/A0 $1.93 7/15/20245,500 shares $10,615.55 No ChangeN/A55 $1.93 6/30/20245,500 shares $13,695.00 -30.4%N/A0 $2.49 6/15/20247,900 shares $19,671.00 +43.6%N/A7.2 $2.49 5/31/20245,500 shares $12,100.00 No ChangeN/A55 $2.20 5/15/20245,500 shares $12,100.00 -6.8%N/A2.5 $2.20 4/30/20245,900 shares $15,635.00 -1.7%N/A0 $2.65 4/15/20246,000 shares $15,900.00 +3.5%N/A60 $2.65 3/31/20245,800 shares $14,964.00 No ChangeN/A29 $2.58 3/15/20245,800 shares $14,152.00 +1.8%N/A58 $2.44 2/29/20245,700 shares $16,188.00 No ChangeN/A0 $2.84 2/15/20245,700 shares $16,188.00 -5.0%N/A0 $2.84 1/15/20244,800 shares $13,632.00 +108.7%N/A48 $2.84 12/31/20232,300 shares $6,532.00 -48.9%N/A4.5 $2.84 12/15/20234,500 shares $11,475.00 +650.0%N/A22.5 $2.55 11/30/2023600 shares $1,434.00 +500.0%N/A0 $2.39 11/15/2023100 shares $239.00 No ChangeN/A1 $2.39 10/15/20239,800 shares $22,625.26 +9,700.0%N/A19.6 $2.31 9/30/2023100 shares $300.00 No ChangeN/A0 $3.00 8/31/202311,600 shares $33,698.00 +11,500.0%N/A43.5 $2.91 8/15/2023100 shares $291.00 -75.0%N/A1 $2.91 7/31/2023400 shares $1,196.00 No ChangeN/A4 $2.99 7/15/2023400 shares $1,232.00 +33.3%N/A4 $3.08 6/30/2023300 shares $1,008.00 +200.0%N/A3 $3.36 6/15/2023100 shares $334.00 -80.0%N/A0.3 $3.34 5/31/2023500 shares $1,465.00 +400.0%N/A0 $2.93 5/15/2023100 shares $293.00 -75.0%N/A1 $2.93 4/30/2023400 shares $1,152.00 +100.0%N/A4 $2.88$5,000 DOGE check? (Ad)Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.Everything you need to know is right here. 4/15/2023200 shares $542.00 -97.8%N/A0 $2.71 3/31/20239,200 shares $24,932.00 -27.6%N/A92 $2.71 3/15/202312,700 shares $39,497.00 +1,487.5%N/A63.5 $3.11 2/28/2023800 shares $2,344.00 +14.3%N/A8 $2.93 2/15/2023700 shares $2,408.00 -95.5%N/A0 $3.44 1/31/202315,700 shares $54,008.00 +15,600.0%N/A52.3 $3.44 1/15/2023100 shares $347.00 -97.1%N/A0.3 $3.47 12/30/20223,500 shares $11,445.00 -60.7%N/A0.7 $3.27 12/15/20228,900 shares $20,648.00 +8,800.0%N/A22.3 $2.32 11/30/2022100 shares $218.88 -90.9%N/A1 $2.19 11/15/20221,100 shares $2,519.00 -80.4%N/A1.1 $2.29 10/31/20225,600 shares $11,697.84 +30.2%N/A56 $2.09 10/15/20224,300 shares $8,901.00 +4,200.0%N/A2.3 $2.07 9/30/2022100 shares $193.00 -66.7%N/A1 $1.93 9/15/2022300 shares $780.00 -97.7%N/A1.5 $2.60 8/31/202212,800 shares $35,840.00 +236.8%N/A8.5 $2.80 8/15/20223,800 shares $10,564.00 +11.8%N/A12.7 $2.78 7/31/20223,400 shares $10,744.00 +6.3%N/A34 $3.16 7/15/20223,200 shares $8,640.00 -3.0%N/A32 $2.70 6/30/20223,300 shares $8,580.00 -15.4%N/A1.2 $2.60 6/15/20223,900 shares $10,803.00 -54.7%N/A39 $2.77 5/31/20228,600 shares $24,338.00 +34.4%N/A86 $2.83 5/15/20226,400 shares $18,112.00 -4.5%N/A32 $2.83 4/30/20226,700 shares $18,391.50 +8.1%N/A67 $2.75 4/15/20226,200 shares $18,910.00 +51.2%N/A12.4 $3.05 3/31/20224,100 shares $14,186.00 -93.9%N/A41 $3.46 3/15/202267,000 shares $241,870.00 -10.8%N/A0 $3.61 2/28/202275,100 shares $271,111.00 +1,004.4%N/A751 $3.61 2/15/20226,800 shares $25,228.00 -70.0%N/A5.7 $3.71 1/31/202222,700 shares $85,579.00 +57.6%N/A37.8 $3.77 1/15/202214,400 shares $62,640.00 +5.1%N/A0 $4.35 12/31/202113,700 shares $59,595.00 +407.4%N/A5.1 $4.35 12/15/20212,700 shares $13,743.00 -52.6%N/A1.4 $5.09 11/30/20215,700 shares $28,618.56 +1.8%N/A6.3 $5.02 11/15/20215,600 shares $28,000.00 -51.7%N/A3.1 $5.00 10/29/202111,600 shares $65,656.00 -6.5%N/A4.1 $5.66 10/15/202112,400 shares $73,160.00 +63.2%N/A6.5 $5.90 9/30/20217,600 shares $47,500.00 -26.2%N/A0.7 $6.25 9/15/202110,300 shares $58,504.00 -94.6%N/A0.7 $5.68 8/31/2021191,300 shares $679,115.00 -49.5%N/A956.5 $3.55 8/13/2021378,500 shares $1.22 million -0.1%N/A3785 $3.22 7/30/2021378,700 shares $1.19 million +0.2%N/A3787 $3.15 7/15/2021378,100 shares $1.23 million +0.0%N/A315.1 $3.25 6/30/2021378,000 shares $1.23 million No ChangeN/A315 $3.25 6/15/2021378,000 shares $1.34 million -0.5%N/A3780 $3.55 5/28/2021379,800 shares $1.44 million -10.3%N/A0 $3.80 5/14/2021423,400 shares $1.74 million +2.3%N/A4234 $4.11 4/30/2021414,000 shares $1.85 million +3.3%N/A828 $4.48 4/15/2021400,700 shares $1.80 million +1,627.2%N/A4007 $4.48 3/31/202123,200 shares $102,506.88 -94.2%N/A77.3 $4.42Elon Takes Aim at Social Security (Ad)Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.>>Here are the NINE stocks everyone will wish they own once Elon moves.<< 3/15/2021401,900 shares $1.82 million 0.0%N/A4019 $4.53 2/26/2021402,000 shares $1.79 million -0.1%N/A1340 $4.46 2/12/2021402,300 shares $1.94 million -0.7%N/A365.7 $4.81 1/29/2021405,200 shares $1.75 million No ChangeN/A4052 $4.33 1/15/2021405,500 shares $1.91 million 0.0%N/A1013.8 $4.72 12/31/2020405,200 shares $1.72 million -0.1%N/A368.4 $4.24 12/15/2020405,500 shares $1.77 million 0.0%N/A1013.8 $4.36 11/30/2020405,600 shares $2.21 million -0.4%N/A450.7 $5.45 11/15/2020407,100 shares $1.81 million No ChangeN/A1017.8 $4.45 10/30/2020407,100 shares $1.51 million +0.2%N/A508.9 $3.70 10/15/2020406,300 shares $1.66 million -0.1%N/A677.2 $4.08 9/30/2020406,600 shares $1.55 million -3.1%N/A4066 $3.80 9/15/2020419,700 shares $1.73 million +3.3%N/A182.5 $4.13 8/31/2020406,200 shares $2.62 million No ChangeN/A2031 $6.45 8/14/2020406,200 shares $2.62 million +0.2%N/A1354 $6.44 7/31/2020405,500 shares $2.56 million No ChangeN/A0 $6.33 7/15/2020405,500 shares $2.56 million No ChangeN/A4055 $6.33 6/30/2020405,500 shares $2.46 million +1,897.5%N/A2027.5 $6.06 6/15/202020,300 shares $128,905.00 +0.5%N/A40.6 $6.35 5/29/202020,200 shares $125,846.00 -95.0%N/A0 $6.23 5/15/2020405,200 shares $2.86 million No ChangeN/A193 $7.07 4/30/2020405,200 shares $2.66 million No ChangeN/A4052 $6.57 4/15/2020405,200 shares $2.24 million 0.0%N/A405.2 $5.53 3/31/2020405,300 shares $2.72 million -0.6%N/A579 $6.70 3/13/2020407,900 shares $2.00 million +0.6%N/A4079 $4.90 2/28/2020405,300 shares $2.97 million -4.8%N/A4053 $7.34 IPHYF Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 500 shares of IPHYF short. Learn More on Innate Pharma's current short interest. How does Innate Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: Replimune Group, Inc. (11.00%), Ginkgo Bioworks Holdings, Inc. (22.61%), Anavex Life Sciences Corp. (27.55%), Opthea Limited (0.27%), LENZ Therapeutics, Inc. (11.14%), Sana Biotechnology, Inc. (36.75%), Relay Therapeutics, Inc. (9.36%), Valneva SE (0.05%), Allogene Therapeutics, Inc. (22.76%), Immatics (8.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHYF is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHYF, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHYF, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies Replimune Group Short Interest Ginkgo Bioworks Short Interest Anavex Life Sciences Short Interest Opthea Short Interest LENZ Therapeutics Short Interest Sana Biotechnology Short Interest Relay Therapeutics Short Interest Valneva Short Interest Allogene Therapeutics Short Interest Immatics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:IPHYF) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
